"Cardiomegaly" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Descriptor ID |
D006332
|
| MeSH Number(s) |
C14.280.195 C23.300.775.250
|
| Concept/Terms |
Cardiomegaly- Cardiomegaly
- Heart Enlargement
- Enlargement, Heart
- Enlarged Heart
- Heart, Enlarged
|
Below are MeSH descriptors whose meaning is more general than "Cardiomegaly".
Below are MeSH descriptors whose meaning is more specific than "Cardiomegaly".
This graph shows the total number of publications written about "Cardiomegaly" by people in this website by year, and whether "Cardiomegaly" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 3 | 3 | 6 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 3 | 1 | 4 |
| 2011 | 2 | 3 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 1 | 4 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiomegaly" by people in Profiles.
-
Stabilisation of PRCP by deubiquitinase-targeting chimera (DUBTAC) to replenish autophagy for ameliorating pathological cardiac hypertrophy. Br J Pharmacol. 2025 Nov; 182(21):5317-5339.
-
Pathways to precision medicine: deciphering the secrets of physiological and pathological atrial enlargement. Clin Sci (Lond). 2024 Sep 18; 138(18):1173-1177.
-
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024 01 16; 149(3):227-250.
-
Biomimetic cardiac tissue culture model (CTCM) to emulate cardiac physiology and pathophysiology ex vivo. Commun Biol. 2022 09 09; 5(1):934.
-
Crucial Role of Mammalian Glutaredoxin 3 in Cardiac Energy Metabolism in Diet-induced Obese Mice Revealed by Transcriptome Analysis. Int J Biol Sci. 2021; 17(11):2871-2883.
-
Metabolic remodeling precedes mTORC1-mediated cardiac hypertrophy. J Mol Cell Cardiol. 2021 09; 158:115-127.
-
The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. Cell Metab. 2021 03 02; 33(3):629-648.e10.
-
Insulin receptor substrates differentially exacerbate insulin-mediated left ventricular remodeling. JCI Insight. 2020 03 26; 5(6).
-
Determinants of Cardiac Growth and Size. Cold Spring Harb Perspect Biol. 2020 03 02; 12(3).
-
Sodium butyrate attenuates angiotensin II-induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6-dependent mechanism. J Cell Mol Med. 2019 12; 23(12):8139-8150.